Effects of KRAS mutation and polymorphism on the risk and prognosis of oral squamous cell carcinoma

Head and Neck

Volumn 34, Issue 5, 2012, Pages 663-666

  Wang, Wen Yi ^a   Chien, Yi Chih ^b   Wong, Yong Kie ^c   Lin, Yan Liang ^b   Lin, Jin Ching ^c,d,e  

^a HUNGKUANG UNIVERSITY   (Taiwan)

^b NATIONAL CHANGHUA UNIVERSITY OF EDUCATION   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

KRAS; mutation; oral cavity; polymorphism; squamous cell carcinoma

Indexed keywords

K RAS PROTEIN;

ADULT; ARTICLE; BLOOD CELL; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN TISSUE; MALE; MOUTH CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; DNA PRIMERS; EXONS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84859762134     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21792     Document Type: Article

References (22)

1. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937-1944.
2. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945-1952.
3. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 2005; 27: 843-850.
4. Sheu JJ, Hua CH, Wan L, et al. Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res 2009; 69: 2568-2576.
5. Laimer K, Spizzo G, Gastl G, et al. High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analysis. Oral Oncol 2007; 43: 193-198.
6. Yarden Y, Sliwkowski MX,. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
7. Woo T, Okudela K, Yazawa T, et al. Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas. Lung Cancer 2009; 65: 355-362.
8. Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007; 13: 2890-2896.
9. LiÃvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995.
10. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96: 1166-1169.
11. Chang SE, Bhatia P, Johnson NW, et al. Ras mutations in United Kingdom examples of oral malignancies are infrequent. Int J Cancer 1991; 48: 409-412.
12. Yarbrough WG, Shores C, Witsell DL, Weissler MC, Fidler ME, Gilmer TM,. Ras mutations and expression in head and neck squamous cell carcinomas. Laryngoscope 1994; 104 (11 Pt 1): 1337-1347.
13. Saranath D, Chang SE, Bhoite LT, et al. High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India. Br J Cancer 1991; 63: 573-578.
14. Chen K, Rajewsky N,. Natural selection on human microRNA binding sites inferred from SNP data. Nat Genet 2006; 38: 1452-1456.
15. Saunders MA, Liang H, Li WH,. Human polymorphism at microRNAs and microRNA target sites. Proc Natl Acad Sci U S A 2007; 104: 3300-3305.
16. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005; 120: 635-647.
17. Chin LJ, Ratner E, Leng S, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3â untranslated region increases non-small cell lung cancer risk. Cancer Res 2008; 68: 8535-8540.
18. Yu Z, Li Z, Jolicoeur N, et al. Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. Nucleic Acids Res 2007; 35: 4535-4541.
19. Johnson CD, Esquela-Kerscher A, Stefani G, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007; 67: 7713-7722.
20. Esquela-Kerscher A, Trang P, Wiggins JF, et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 2008; 7: 759-764.
21. Slack F,. let-7 microRNA reduces tumor growth. Cell Cycle 2009; 8: 1823.
22. Christensen BC, Moyer BJ, Avissar M, et al. A let-7 microRNA binding site polymorphism in the KRAS 3â UTR is associated with reduced survival in oral cancers. Carcinogenesis 2009; 30: 1003-1007.